Global Minimal Residual Disease Market Size

Statistics for the 2023 & 2024 Global Minimal Residual Disease market size, created by Mordor Intelligence™ Industry Reports. Global Minimal Residual Disease size report includes a market forecast to 2029 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of Global Minimal Residual Disease Industry

Minimal Residual Disease Market Size
share button
Study Period 2019 - 2029
Market Size (2024) USD 1.90 Billion
Market Size (2029) USD 3.49 Billion
CAGR (2024 - 2029) 12.88 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players


*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

Minimal Residual Disease Market Analysis

The Global Minimal Residual Disease Market size is estimated at USD 1.9 billion in 2024, and is expected to reach USD 3.49 billion by 2029, growing at a CAGR of 12.88% during the forecast period (2024-2029).

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. Since the beginning of the COVID-19 pandemic, measures have been taken to increase the admissions of covid patients and reduce the number of non-covid patients in the hospitals, leading to postponing the treatment. A study titled 'Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study' in September 2020 reported that a total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), and staff shortage (17.98%), and restricted access to medications (9.83%). According to an article titled 'What is the Clinical Impact of COVID-19 on Cancer Patients?' in June 2020, the increased vulnerability of cancer patients to COVID-19, particularly to the severe effects of this infectious disease, has led some patients to delay or pause their anti-cancer treatments to reduce their exposure to potentially infected people, and this condition during initial pandemic phase affected the market adversely. Such studies indicate that cancer care was severely impacted, subsequently impacting the market growth. Hence, there is an overall negative impact of the COVID-19 pandemic on the market's growth.

The factors propelling the growth of the minimal residual disease market are the rising prevalence of various types of cancer worldwide and the increasing awareness among people to confirm the presence of carcinogens. The patients undergoing continued cancer treatment are expected to be the most important element driving the minimal residual disease market forward. In addition, the rising adoption of personalized medicines for the treatment and rising research and development activities contribute to the market's growth.

The increasing number of people suffering from various cancers is the key driving factor for the minimal residual disease market growth. For instance, as per the American Society of Clinical Oncology February 2021 report, an estimated 235,760 adults (119,100 men and 116,6600 women) in the United States were expected to be diagnosed with lung cancer. For instance, Globocan, 2020, it found that there are 18.3% new cases of cancers in India, and cervical cancer accounted for 9.4% of all cancers. For instance, according to statistics published by the American Cancer Society (ACS) updates from January 2022, approximately 26,560 new cases of stomach cancer are projected to be detected in the United States in 2021, with 16,160 males and 10,400 women. According to the statistics published by the National Breast Cancer Foundation, in July 2021, approximately 63% of breast cancer patients have been diagnosed with local-stage breast cancer, 27% with regional stage, and 6% with a distant (metastatic) disease.

In addition, the rising prevalence of blood cancer worldwide increases the demand for better treatment options and accuracy in removing the residual cancerous cells, which is likely to increase the demand for a minimal residual disease market. According to the statistics published by the American Cancer Society, in January 2022, 34,920 new cases of multiple myeloma were estimated to be diagnosed in the United States.

However, the high cost of research and development activities will likely hinder the market's growth over the forecast period.

Minimal Residual Disease Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)